HeidelbergCapital is an independent Private Equity Funds Group, specialising in Secondary Direct Investments, e.g. the acquisition of shareholdings in companies previously held by private equity/venture capital funds or banks.

News

04.02.2016


Nanogate
driving international growth forward – Strong foreign business expected for 2016

21.01.2016


vasopharm
Announces EUR 20 million Fundraising to Progress Treatment for Traumatic Brain Injury

10.10.2015


Nanogate
is „Entrepreneur Of The Year 2015“

23.04.2015


Nanogate
plans to increase sales to over EUR 80 million – Preliminary figures for 2014 exceeded

13.04.2015


HeidelbergCapital
& Creathor Venture exit Accovion

09.04.2015


Nanogate
expands technology portfolio: creation of a new platform for the multifunctional metallisation of surfaces

About us


HeidelbergCapital was founded mid 2007. The company is jointly managed by Dr. Clemens Doppler and Prof. Dr. Martin Weiblen, former Managing Director of a multi-billion family office in London/U.K. and advisor to several Life Science-Funds. Dr. Clemens Doppler is a former Partner at 3i, the British Private Equity Group. The New York based Private Equity Investor Auda has committed c150m USD for the first fund, HeidelbergCapital Private Equity Fund I.

The portfolio of HeidelbergCapital ranges from investments in later stage venture companies with a proven business model to established mid-size operations. As an active partner, HeidelbergCapital supports the companies in strategic business decisions, but also provides, where appropriate, funding for further growth.

Investments

4sc – Martinsried (D)

Drug development company

ApSec – Stockstadt (D)

Data security solutions

MerLion – Singapur

Drug development company

MobileCity – Saarbrücken (D)

Mobile Payment Solutions

Nanogate – Saarbrücken (D)

High performance surfaces

Nextevolution – Hamburg (D)

IT solutions and services